Business News

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

June 28, 2024

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.

Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases

June 18, 2024

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.

Pushing Boundaries to Revolutionize Chronic Inflammation Therapy

June 14, 2024

Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.

Syntegon Acquires Telstar

June 11, 2024

Syntegon will expand its processing and packaging by acquiring the Spanish equipment supplier.

Sterling Invests in Expansion of Integrated ADC Services

May 31, 2024

Sterling is strengthening its development and manufacturing services for ADCs with a dedicated GMP suite at its Wisconsin facility.

Lilly Raises Investment in Indiana Site to $9 Billion to Expand API Manufacturing

May 30, 2024

Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.

Johnson & Johnson to Acquire Global Rights to Numab Therapeutics’ Bispecific Antibody for Atopic Dermatitis in $1.25 Billion Deal

May 30, 2024

Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.

AGC Biologics Partners with BioConnection to Offer Biopharma Drug Substance and Drug Product Development and Manufacturing

May 25, 2024

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

Biogen to Acquire HI-Bio in Deal Worth Potentially Up to $1.8 Billion

May 24, 2024

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.

Merck KGaA Announces $600 Million Deal to Acquire Mirus Bio

May 24, 2024

With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.